Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: Assessment after 2 years

The impact of single dose mass drug administration of diethylcarbamazine (DEC), DEC with albendazole (ALB), and ivermectin (IVR) with albendazole, was examined on the human bancroftian filarial infections in village scale trials in south India, from a follow-up study after 2 years. The treatment arms administered with DEC alone and DEC + ALB demonstrated long-term benefits in reducing microfilaraemia significantly (P < 0.05), while antigenaemia reduction was negligible. The arm with ALB + IVR did not show such reductions. Among the antigenaemic and microfilaraemic individuals, 87% became amicrofilaraemic in DEC + ALB arm, which were higher than that observed in the other 2 treatment arms. Among amicrofilaraemics (but Ag+), nearly 35% cleared of infection in DEC + ALB, while 26% and 6% in DEC alone and IVR + ALB arms, respectively. The drug combination DEC + ALB was observed to demonstrate a significant impact in reducing filarial infection even after 2 years post treatment.